Banerjee Subhashis 4

What Happened

• Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics (ARTV), was granted 102,000 restricted stock units (RSUs) on 2026-02-15. The grant is recorded at $0.00 per share (acquisition value $0) in the Form 4 filing and is reported as an award/grant (transaction code A).

Key Details

• Transaction date: 2026-02-15 (grant)
• Filing date: 2026-02-18 (filed three days after the transaction date; this appears to be later than the usual two-business-day Form 4 deadline)
• Amount: 102,000 RSUs granted; price reported $0.00 (acquisition value $0)
• Footnote: Awarded under the Issuer's 2024 Equity Incentive Plan (per footnote F1)
• Shares owned after transaction: not specified in the filing
• Transaction type code: A = Award/Grant

Context

• RSUs are a grant of future shares subject to vesting; no cash was exchanged at grant. They generally convert into shares only after vesting and may be taxable at vesting. This is neither an open-market purchase nor a sale—it's a compensation award. Investors should watch for the grant's vesting schedule and potential dilution, but the filing itself does not indicate any immediate sale or purchase by the insider.